High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

F.R. Mauro; S. Molica; S. Soddu; F. Ilariucci; M. Coscia; F. Zaja; E. Angelucci; F. Re; A.M. Liberati; A. Tedeschi; G. Reda; D. Pietrasanta; A. Gozzetti; R. Battistini; G. Del Poeta; C. Musolino; M. Nanni; A. Piciocchi; M. Vignetti; A. Neri; F. Albano; A. Cuneo; I.D. Giudice; I.D. Starza; M.S. de Propris; S. Raponi; A.R. Guarini; R. Foà

doi:10.3324/HAEMATOL.2019.235705

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

F.R. Mauro, S. Molica, S. Soddu, F. Ilariucci, M. Coscia, F. Zaja, E. Angelucci, F. Re, A.M. Liberati, A. Tedeschi, G. Reda, D. Pietrasanta, A. Gozzetti, R. Battistini, G. Del Poeta, C. Musolino, M. Nanni, A. Piciocchi, M. Vignetti, A. NeriF. Albano, A. Cuneo, I.D. Giudice, I.D. Starza, M.S. de Propris, S. Raponi, A.R. Guarini, R. Foà

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Haematologica
Volume	105
Issue number	5
DOIs	https://doi.org/10.3324/HAEMATOL.2019.235705
Publication status	Published - 2020

Keywords

ONCOLOGIA
STUDIO CLINICO
RIS

Access to Document

10.3324/HAEMATOL.2019.235705

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084656971&doi=10.3324%2fHAEMATOL.2019.235705&partnerID=40&md5=45980779d3c77f938250a9e37deaa6c1

Cite this

Mauro, F. R., Molica, S., Soddu, S., Ilariucci, F., Coscia, M., Zaja, F., Angelucci, E., Re, F., Liberati, A. M., Tedeschi, A., Reda, G., Pietrasanta, D., Gozzetti, A., Battistini, R., Del Poeta, G., Musolino, C., Nanni, M., Piciocchi, A., Vignetti, M., ... Foà, R. (2020). High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica, 105(5). https://doi.org/10.3324/HAEMATOL.2019.235705

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). / Mauro, F.R.; Molica, S.; Soddu, S.; Ilariucci, F.; Coscia, M.; Zaja, F.; Angelucci, E.; Re, F.; Liberati, A.M.; Tedeschi, A.; Reda, G.; Pietrasanta, D.; Gozzetti, A.; Battistini, R.; Del Poeta, G.; Musolino, C.; Nanni, M.; Piciocchi, A.; Vignetti, M.; Neri, A.; Albano, F.; Cuneo, A.; Giudice, I.D.; Starza, I.D.; de Propris, M.S.; Raponi, S.; Guarini, A.R.; Foà, R.

In: Haematologica, Vol. 105, No. 5, 2020.

Research output: Contribution to journal › Article › peer-review

Mauro, FR, Molica, S, Soddu, S , Ilariucci, F, Coscia, M, Zaja, F, Angelucci, E, Re, F, Liberati, AM, Tedeschi, A, Reda, G, Pietrasanta, D, Gozzetti, A, Battistini, R, Del Poeta, G, Musolino, C, Nanni, M, Piciocchi, A, Vignetti, M, Neri, A, Albano, F, Cuneo, A, Giudice, ID, Starza, ID, de Propris, MS, Raponi, S, Guarini, AR & Foà, R 2020, 'High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)', Haematologica, vol. 105, no. 5. https://doi.org/10.3324/HAEMATOL.2019.235705

Mauro, F.R. ; Molica, S. ; Soddu, S. ; Ilariucci, F. ; Coscia, M. ; Zaja, F. ; Angelucci, E. ; Re, F. ; Liberati, A.M. ; Tedeschi, A. ; Reda, G. ; Pietrasanta, D. ; Gozzetti, A. ; Battistini, R. ; Del Poeta, G. ; Musolino, C. ; Nanni, M. ; Piciocchi, A. ; Vignetti, M. ; Neri, A. ; Albano, F. ; Cuneo, A. ; Giudice, I.D. ; Starza, I.D. ; de Propris, M.S. ; Raponi, S. ; Guarini, A.R. ; Foà, R. / High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). In: Haematologica. 2020 ; Vol. 105, No. 5.

@article{3b3e975a4bb3429d8fb804d3b1947901,

title = "High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)",

keywords = "ONCOLOGIA, STUDIO CLINICO, RIS",

author = "F.R. Mauro and S. Molica and S. Soddu and F. Ilariucci and M. Coscia and F. Zaja and E. Angelucci and F. Re and A.M. Liberati and A. Tedeschi and G. Reda and D. Pietrasanta and A. Gozzetti and R. Battistini and {Del Poeta}, G. and C. Musolino and M. Nanni and A. Piciocchi and M. Vignetti and A. Neri and F. Albano and A. Cuneo and I.D. Giudice and I.D. Starza and {de Propris}, M.S. and S. Raponi and A.R. Guarini and R. Fo{\`a}",

year = "2020",

doi = "10.3324/HAEMATOL.2019.235705",

language = "English",

volume = "105",

journal = "Haematologica",

issn = "1592-8721",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

AU - Mauro, F.R.

AU - Molica, S.

AU - Soddu, S.

AU - Ilariucci, F.

AU - Coscia, M.

AU - Zaja, F.

AU - Angelucci, E.

AU - Re, F.

AU - Liberati, A.M.

AU - Tedeschi, A.

AU - Reda, G.

AU - Pietrasanta, D.

AU - Gozzetti, A.

AU - Battistini, R.

AU - Del Poeta, G.

AU - Musolino, C.

AU - Nanni, M.

AU - Piciocchi, A.

AU - Vignetti, M.

AU - Neri, A.

AU - Albano, F.

AU - Cuneo, A.

AU - Giudice, I.D.

AU - Starza, I.D.

AU - de Propris, M.S.

AU - Raponi, S.

AU - Guarini, A.R.

AU - Foà, R.

PY - 2020

Y1 - 2020

KW - ONCOLOGIA

KW - STUDIO CLINICO

KW - RIS

U2 - 10.3324/HAEMATOL.2019.235705

DO - 10.3324/HAEMATOL.2019.235705

M3 - Article

VL - 105

JO - Haematologica

JF - Haematologica

SN - 1592-8721

IS - 5

ER -